Invitrogen Corporation Announces Broad Kinase Screening Agreement With Locus Pharmaceuticals, Inc.

Invitrogen Corporation (Nasdaq:IVGN - News), a provider of essential life science technologies for disease research and drug discovery, today announced a contract to provide Locus Pharmaceuticals, Inc. with kinase screening services through its SelectScreen(TM) platform. Invitrogen's service will support Locus' internal kinase discovery programs, principally in the areas of cancer and inflammation. Financial details of the transaction were not disclosed.

Back to news